Health Apr 14

A company logo is seen at a Pfizer office in Dublin
Pfizer abandons potential obesity treatment pill

The drugmaker said Tuesday that it would stop studying danuglipron after a participant in one of its trials experienced a possible drug-induced liver injury that ended once the person stopped taking the treatment.